Berbamine dihydrochloride

Catalog No.S3609 Batch:S360901

Print

Technical Data

Formula

C37H40N2O6.2HCl
Molecular Weight 681.65 CAS No. 6078-17-7
Solubility (25°C)* In vitro DMSO 100 mg/mL (146.7 mM)
Water 100 mg/mL (146.7 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Berbamine (BA, BBM) dihydrochloride, a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. Berbamine (BA, BBM) dihydrochloride induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).
Targets
Bcr-Abl [4] NF-κB [5] CaMKII [1]
In vitro

Berbamine (BBM) potently suppresses liver cancer cell proliferation and induces cancer cell death by targeting Ca2+/calmodulin-dependent protein kinase II (CAMKII). Through targeting CAMKII, BBM's inhibition on cancer cells might have broader effects beyond affecting JAK/STAT3 and p210bcr-abl, because CAMKIIγ directly impacts many other signal pathways including STAT1, NF-κB, JNK, ERK1/2, FOXO1, and Wnt/β-catenin[1]. BBM can effectively inhibit tumor metastasis by suppressing cell proliferation, migration and invasion in highly metastatic breast cancer cells under in vitro condition[2]. Berbamine inhibits proliferation of K562-r cells both in vitro and in vivo. Berbamine-induced apoptosis in K562-r cells appear to occur through a mechanism involving Bcl-2 family proteins, as well as mdr-1 mRNA and P-gp protein. Berbamine in combination with imatinib restore the chemo-sensitivity of K562-r cells to imatinib[3].
In vivo

BBM inhibits the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice, and down-regulated the self-renewal abilities of liver cancer initiating cells[1]. BBM shows its anticancer activity by induction of apoptosis, cell cycle arrest and reversing multidrug resistance. Though BBM is a potent drug but its half-life in blood plasma is very short, owing to its quick renal clearance[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    epithelial liver cancer cell lines, including Huh7, HepG2, MHCC97H, and PLC/PRF/5

  • Concentrations

    0-80 μg/ml

  • Incubation Time

    72 h

  • Method

    Cell proliferation is assayed 72 hours after BBM treatment for liver cancer cells with epithelial morphology.
Animal Study:

[1]
  • Animal Models

    NOD/SCID mouse

  • Dosages

    100 mg/kg

  • Administration

    oral

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.